Eikon Therapeutics is a new biopharmaceutical company employing the revolutionary technology of single molecule imaging at the interface of chemistry, engineering and biology to discover novel treatments for life-threatening diseases. Eikon’s live cell imaging drug discovery platform is built on groundbreaking innovations from its founders who pioneered the field of in vivo single-molecule microscopy (Nobel Prize, 2014).

We are building a passionate and creative team eager to apply their talents to empower interdisciplinary scientific exploration, inaugurate a radically novel drug-discovery paradigm and ultimately create new medicines for patients with severe unmet needs.